Immunocore (IMCR)

• Market cap: $1.42B
• 1 day: -0.35%
• 5 days: -0.74%
• 1 month: -12.65%
• 3 months: -14.65%
• 6 months: -19.36%
• Year to date: -60.47%
• 1 year: -51.42%
• 5 years: -34.44%
• 10 years: -34.44%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Employees: 497

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

34% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 35

0.44% more ownership

Funds ownership: 90.02% [Q2] → 90.46% (+0.44%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

5% less capital invested

Capital invested by funds: $1.49B [Q2] → $1.41B (-$80.4M) [Q3]

7% less funds holding

Funds holding: 135 [Q2] → 126 (-9) [Q3]

32% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 28

56% less call options, than puts

Call options by funds: $6.62M | Put options by funds: $15M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $24 15% downside
• Avg. target: $54 89% upside
• High target: $100 253% upside

5 analyst ratings

• positive: 2 40%
• neutral: 2 40%
• negative: 1 20%

Morgan Stanley Andrew Galler 0% 1-year accuracy 0 / 1 met price target	24% upside $35	Equal-Weight Downgraded	13 Dec 2024
Mizuho Graig Suvannavejh 41% 1-year accuracy 12 / 29 met price target	34% upside $38	Neutral Downgraded	11 Nov 2024
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target	151% upside $71	Buy Maintained	7 Nov 2024
UBS David Dai 18% 1-year accuracy 2 / 11 met price target	15% downside $24	Sell Initiated	24 Oct 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target	253% upside $100	Buy Reiterated	24 Oct 2024